TWI912383B - 醫藥化合物之結晶形式、其製備方法、包含其之組合物及其用途 - Google Patents
醫藥化合物之結晶形式、其製備方法、包含其之組合物及其用途Info
- Publication number
- TWI912383B TWI912383B TW110136766A TW110136766A TWI912383B TW I912383 B TWI912383 B TW I912383B TW 110136766 A TW110136766 A TW 110136766A TW 110136766 A TW110136766 A TW 110136766A TW I912383 B TWI912383 B TW I912383B
- Authority
- TW
- Taiwan
- Prior art keywords
- compound
- crystalline form
- disease
- pharmaceutical composition
- sample
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20199934.9A EP3978474A1 (en) | 2020-10-02 | 2020-10-02 | Crystalline forms of a pharmaceutical compound |
| EP20199934.9 | 2020-10-02 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW202229236A TW202229236A (zh) | 2022-08-01 |
| TWI912383B true TWI912383B (zh) | 2026-01-21 |
Family
ID=72744696
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW110136766A TWI912383B (zh) | 2020-10-02 | 2021-10-01 | 醫藥化合物之結晶形式、其製備方法、包含其之組合物及其用途 |
Country Status (19)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3978474A1 (en) * | 2020-10-02 | 2022-04-06 | Azafaros B.V. | Crystalline forms of a pharmaceutical compound |
| IL314212A (en) * | 2022-01-10 | 2024-09-01 | Azafaros B V | Treatment of GM2 gangliosidosis |
| EP4209215A1 (en) * | 2022-01-10 | 2023-07-12 | Azafaros B.V. | Treatment of gm2 gangliosidosis |
| AU2025214578A1 (en) | 2024-02-01 | 2026-08-13 | Azafaros B.V. | Treatment of gm1 gangliosidosis |
| EP4595964A1 (en) | 2024-02-01 | 2025-08-06 | Azafaros B.V. | Treatment of gm1 gangliosidosis |
| EP4678174A1 (en) * | 2024-07-11 | 2026-01-14 | Azafaros B.V. | Nizubaglustat for use in the treatment of lysosomal storage disorders |
| WO2026013261A1 (en) * | 2024-07-11 | 2026-01-15 | Azafaros B.V. | Nizubaglustat for use in the treatment of lysosomal storage disorders |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015147639A1 (en) * | 2014-03-27 | 2015-10-01 | Academisch Medisch Centrum | N-(5-((aryl or heteroaryl)methyloxy)pentyl)-substituted iminosugars as inhibitors of glucosylceramide synthase |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190195897A1 (en) * | 2015-06-24 | 2019-06-27 | Universiteit Leiden | Glycosylated metabolites |
| EP3978474A1 (en) * | 2020-10-02 | 2022-04-06 | Azafaros B.V. | Crystalline forms of a pharmaceutical compound |
-
2020
- 2020-10-02 EP EP20199934.9A patent/EP3978474A1/en not_active Withdrawn
-
2021
- 2021-10-01 KR KR1020247012671A patent/KR20240056628A/ko active Pending
- 2021-10-01 EP EP23191550.5A patent/EP4295847A3/en active Pending
- 2021-10-01 FI FIEP21798287.5T patent/FI4114826T3/fi active
- 2021-10-01 DK DK21798287.5T patent/DK4114826T3/da active
- 2021-10-01 BR BR122022018214-3A patent/BR122022018214A2/pt not_active Application Discontinuation
- 2021-10-01 TW TW110136766A patent/TWI912383B/zh active
- 2021-10-01 MX MX2023003618A patent/MX2023003618A/es unknown
- 2021-10-01 CA CA3193939A patent/CA3193939C/en active Active
- 2021-10-01 CN CN202180067242.0A patent/CN116390910A/zh active Pending
- 2021-10-01 KR KR1020237014953A patent/KR102659466B1/ko active Active
- 2021-10-01 WO PCT/EP2021/077100 patent/WO2022069709A1/en not_active Ceased
- 2021-10-01 EP EP21798287.5A patent/EP4114826B1/en active Active
- 2021-10-01 US US18/029,842 patent/US12116344B2/en active Active
- 2021-10-01 PE PE2023001212A patent/PE20240138A1/es unknown
- 2021-10-01 AU AU2021353055A patent/AU2021353055B2/en active Active
- 2021-10-01 JP JP2022577645A patent/JP7809655B2/ja active Active
- 2021-10-01 MA MA58885A patent/MA58885B1/fr unknown
- 2021-10-01 ES ES21798287T patent/ES2964105T3/es active Active
- 2021-10-01 IL IL316634A patent/IL316634A/en unknown
- 2021-10-01 BR BR112022018020-9A patent/BR112022018020B1/pt active IP Right Grant
- 2021-10-01 IL IL301882A patent/IL301882B2/en unknown
-
2022
- 2022-12-20 AU AU2022291486A patent/AU2022291486B2/en active Active
-
2023
- 2023-03-30 CL CL2023000943A patent/CL2023000943A1/es unknown
- 2023-10-30 ZA ZA2023/10184A patent/ZA202310184B/en unknown
-
2024
- 2024-02-02 JP JP2024015037A patent/JP2024054192A/ja active Pending
- 2024-08-30 US US18/821,921 patent/US20250059137A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015147639A1 (en) * | 2014-03-27 | 2015-10-01 | Academisch Medisch Centrum | N-(5-((aryl or heteroaryl)methyloxy)pentyl)-substituted iminosugars as inhibitors of glucosylceramide synthase |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102659466B1 (ko) | 약제학적 화합물의 결정형 | |
| TWI922809B (zh) | N-(4-(4-(環丙基甲基)哌嗪-1-羰基)苯基)喹啉-8-磺醯胺之結晶型 | |
| EA019819B1 (ru) | Кристаллическая полиморфная форма с ингибитора белка, активирующего 5-липоксигеназу, фармацевтическая композиция на ее основе и применение в лечении | |
| EA023435B1 (ru) | Фармацевтическая композиция, включающая новый холиновый сокристалл эпалрестата | |
| TW202337456A (zh) | Gm2神經節苷脂症之治療 | |
| KR20260026542A (ko) | 포시펜 d-타르트레이트의 고체 형태 | |
| US11643428B2 (en) | Therapeutic drug for neurodegenerative disease and application thereof | |
| NZ798892B2 (en) | Crystalline forms of a pharmaceutical compound | |
| EA052826B1 (ru) | Кристаллические формы фармацевтического соединения | |
| HK40087007B (en) | Crystalline forms of a pharmaceutical compound | |
| HK40087007A (en) | Crystalline forms of a pharmaceutical compound | |
| EA045552B1 (ru) | Кристаллические формы фармацевтического соединения | |
| EP4699606A2 (en) | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto |